koryu

NTLA long crispr/cas9

看多
koryu 已更新   
NASDAQ:NTLA   Intellia Therapeutics, Inc.
6
buying NTLA as long term investment in crispr/cas9 technology.
交易進行
評論:
bottom here would paint this channel
評論:
CRISPR stocks soar after chinese scientists start to crispr a human for the first time
評論:
added to position in this last dip, inv h+s, crispr hot!!
評論:
dump it -> go edit
手動結束交易

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。